 RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2020 GLOBE NEWSWIRE -- Liquidia Technologies, Inc. Nasdaq:LQDA, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT technology, today announced that second quarter 2020 financial results will be reported on Monday, August 10, 2020. The company will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and provide a corporate update. The live call may be accessed by dialing 1-877-707-8711 domestic or 1-857-270-6219 international and entering the conference code: 7295403. A live and archived webcast of the call will also be available on the Events Presentations page of the Liquidia website.About LiquidiaLiquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension PAH and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit InformationInvestors: Jason Adair Vice President, Corporate Development and Strategy 919.328.4400 Michael Parks Corporate Communications 484.356.7105 